Search research articles
Contact Us
Filters
Showing results (271-280 of 282) with videos related to
Page
of 29
Sort By:
ACS Medicinal Chemistry Letters
|
March 25, 2017
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia
Dalton King, Christiana Iwuagwu, Jim Cook, et al.
Head & Neck
|
September 28, 2012
Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia
David J Adelstein, John A Ridge, David M Brizel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2024
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
Li Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
Mitchell Machtay, Pedro A Torres-Saavedra, Wade Thorstad, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation
Daniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Plant Direct
|
August 29, 2022
Removing systemic barriers to equity, diversity, and inclusion: Report of the 2019 Plant Science Research Network workshop "Inclusivity in the Plant Sciences"
Natalie A Henkhaus, Wolfgang Busch, Angela Chen, et al.
Journal of Medicinal Chemistry
|
December 14, 2016
Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship
James Cook, F Christopher Zusi, Ivar M McDonald, et al.
JCO Oncology Practice
|
December 4, 2025
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium
Allen S Ho, Justin T Moyers, Shirin Attarian, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists
Mary T Didiuk, David A Griffith, John W Benbow, et al.
Oral Oncology
|
July 18, 2020
A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311
Robert L Ferris, Yael Flamand, F Christopher Holsinger, et al.
Page
of 29
Search research articles
Search
Showing results (271-280 of 282) with videos related to
Sort By:
Page
of 29
ACS Medicinal Chemistry Letters
|
March 25, 2017
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia
Dalton King, Christiana Iwuagwu, Jim Cook, et al.
Head & Neck
|
September 28, 2012
Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia
David J Adelstein, John A Ridge, David M Brizel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2024
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
Li Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
Mitchell Machtay, Pedro A Torres-Saavedra, Wade Thorstad, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation
Daniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Plant Direct
|
August 29, 2022
Removing systemic barriers to equity, diversity, and inclusion: Report of the 2019 Plant Science Research Network workshop "Inclusivity in the Plant Sciences"
Natalie A Henkhaus, Wolfgang Busch, Angela Chen, et al.
Journal of Medicinal Chemistry
|
December 14, 2016
Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship
James Cook, F Christopher Zusi, Ivar M McDonald, et al.
JCO Oncology Practice
|
December 4, 2025
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium
Allen S Ho, Justin T Moyers, Shirin Attarian, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists
Mary T Didiuk, David A Griffith, John W Benbow, et al.
Oral Oncology
|
July 18, 2020
A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311
Robert L Ferris, Yael Flamand, F Christopher Holsinger, et al.
Page
of 29